403 related articles for article (PubMed ID: 21471191)
1. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
2. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
3. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr
Patel A; Yusta B; Matthews D; Charron MJ; Seeley RJ; Drucker DJ
Mol Metab; 2018 Oct; 16():45-54. PubMed ID: 29937214
[TBL] [Abstract][Full Text] [Related]
4. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
Gu W; Winters KA; Motani AS; Komorowski R; Zhang Y; Liu Q; Wu X; Rulifson IC; Sivits G; Graham M; Yan H; Wang P; Moore S; Meng T; Lindberg RA; Véniant MM
Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E624-32. PubMed ID: 20647556
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
[TBL] [Abstract][Full Text] [Related]
6. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet.
Parlevliet ET; de Leeuw van Weenen JE; Romijn JA; Pijl H
Am J Physiol Endocrinol Metab; 2010 Aug; 299(2):E318-24. PubMed ID: 20530733
[TBL] [Abstract][Full Text] [Related]
8. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1.
Patterson JT; Ottaway N; Gelfanov VM; Smiley DL; Perez-Tilve D; Pfluger PT; Tschöp MH; Dimarchi RD
ACS Chem Biol; 2011 Feb; 6(2):135-45. PubMed ID: 20939591
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
10. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
11. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
[TBL] [Abstract][Full Text] [Related]
12. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
[TBL] [Abstract][Full Text] [Related]
13. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production.
Jun LS; Millican RL; Hawkins ED; Konkol DL; Showalter AD; Christe ME; Michael MD; Sloop KW
Diabetes; 2015 Mar; 64(3):819-27. PubMed ID: 25288673
[TBL] [Abstract][Full Text] [Related]
14. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.
Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J
Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795
[TBL] [Abstract][Full Text] [Related]
15. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
16. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys.
Yan H; Gu W; Yang J; Bi V; Shen Y; Lee E; Winters KA; Komorowski R; Zhang C; Patel JJ; Caughey D; Elliott GS; Lau YY; Wang J; Li YS; Boone T; Lindberg RA; Hu S; Véniant MM
J Pharmacol Exp Ther; 2009 Apr; 329(1):102-11. PubMed ID: 19129372
[TBL] [Abstract][Full Text] [Related]
17. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
18. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
20. Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes.
Lang S; Yang J; Yang K; Gu L; Cui X; Wei T; Liu J; Le Y; Wang H; Wei R; Hong T
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
